Radiotherapy to the primary tumour has been much discussed as a possible intervention in patients with newly diagnosed metastatic prostate cancer. Results of the STAMPEDE trial indicate that overall no survival advantage can be achieved by the addition of radiotherapy. However, patients with low volume, oligometastatic disease were shown to benefit in a predefined subgroup analysis. In the current podcast Dr. Parker provides insight on the practice changing impact of the STAMPEDE trial and gives an outlook what is next on the horizon in metastatic prostate cancer therapy.
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